High cholesterol: what is Inclisiran? India's new approach to lowering cholesterol with THIS treatment of two injections per year

India offers a breakthrough drug, Inclisiran, designed to lower high cholesterol. This treatment provides an effective and consistent reduction in bad cholesterol with just two injections per year.

Maintaining healthy cholesterol levels is an essential part of cardiovascular health. In recent years, medical advances have led to the development of several cholesterol-lowering drugs, and one of those breakthrough drugs is Inclisiran. KEM Hospital in Mumbai is currently conducting trials of this promising new drug. It has shown very positive results in trials and is being touted as a potential game changer in cholesterol management. In this article, we will talk about how this drug can help treat high cholesterol, its price, benefits, and more.

INDIA APPROACHES A TWO-YEAR INJECTION TREATMENT TO REDUCE HIGH CHOLESTEROL

LDL cholesterol is often called “bad” cholesterol because higher levels of LDL cholesterol can lead to the buildup of plaque in the arteries, increasing the risk of heart disease and heart problems. Inclisiran, also known by the brand name Leqocin, is a drug specifically made to target LDL cholesterol in the body.

What sets this drug apart from existing cholesterol medications is its rapid mechanism of action. Inclisiran acts as an RNA interference and functions at the genetic level to lower LDL cholesterol in the liver. By inhibiting the production of this specific protein, it helps reduce bad cholesterol in the bloodstream.

WHAT ARE THE COST AND AVAILABILITY OF THE HIGH CHOLESTROL MEDICATION?

Unlike traditional cholesterol-lowering medications that require frequent dosing, Inclisiran stands out in this department. This medication is administered by subcutaneous injection only twice a year. Inclisiran provides steady and effective lowering of LDL cholesterol, freeing patients from the need for frequent medications.

The Drug Controller General of India (DCGI) has approved Inclisiran, under the brand name Sybrava, after the successful completion of trials. The cost is expected to be around Rs 1.2 Lakhs. However, exact pricing information may vary depending on the region and healthcare provider. The pharmaceutical companies are actively involved in negotiations and discussions with healthcare authorities to ensure access to this groundbreaking medicine.

With Inclisiran's unique RNAi mechanism approach, it manages high cholesterol levels, further reducing the risk of cardiovascular disease. Although cost details may vary, this life-enhancing drug has opened doors for people to seek long-term treatment for cholesterol control.